|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Federal Register** / Vol. 66, No. 57 / Friday, March 23, 2001 / Notices | | | | | | | | | | | | | **16271** |
| Activities, National Cancer Institute, National | | | | | limitations imposed by the review and | | | | | Cancer Control, National Institutes of Health, | | | |
| Institutes of Health, 6116 Executive | | | funding cycle. | | | | | | | HHS) | | | |
| Boulevard, 8th Floor, Room 8050, Bethesda, | | | | (Catalogue of Federal Domestic Assistance | | | | | | Dated: March 15, 2001. | | | |
| MD 20852–8328, (301) 496–7930, | | | | Program Nos. 93.392, Cancer Construction; | | | | | |
| **LaVerne Y. Stringfield,** | | | |
| mg85x@nih,gov. | | | | 93.393, Cancer Cause and Prevention | | | | | |
| This notice is being published less than 15 | | | | *Director, Office of Federal Advisory* | | | |
| Research; 93.394, Cancer Detection and | | | | | |
| days prior to the meeting due to the timing | | | | *Committee Policy.* | | | |
| Diagnosis Research; 93.395, Cancer | | | | | |
| limitations imposed by the review and | | | | [FR Doc. 01–7215 Filed 3–22–01; 8:45 am] | | | |
| Treatment Research; 93.396, Cancer Biology | | | | | |
| funding cycle. | | | | **BILLING CODE 4140–01–M** | | | |
| Research; 93.397, Cancer Centers Support; | | | | | |
| (Catalogue of Federal Domestic Assistance | | | | 93.398, Cancer Research Manpower; 93.399, | | | | | |
| Program Nos. 93.392, Cancer Construction; | | | | Cancer Control, National Institutes of Health, | | | | | | **DEPARTMENT OF HEALTH AND HUMAN SERVICES** | | | |
| 93.393, Cancer Cause and Prevention | | | | HHD) | | | | | |
| Research; 93.394, Cancer Detection and | | | | Dated: March 15, 2001. | | | | | |
| Diagnosis Research; 93.395, Cancer | | | |
| **LaVerne Y. Stringfield,** | | | | | |
| Treatment Research; 93.396, Cancer Biology | | | | **National Institutes of Health** | | | |
| Research; 93.397, Cancer Centers Support; | | | | *Director, Office of Federal Advisory* | | | | | |
| 93.398, Cancer Research Manpower; 93.399, | | | | *Committee Policy.* | | | | | | **National Cancer Institute; Notice of Closed Meeting** | | | |
| Center Control, National Institutes of Health, | | | | [FR Doc. 01–7214 Filed 3–22–01; 8:45 am] | | | | | |
| HHS) | | | |
| **BILLING CODE 4140–01–M** | | | | | |
| Dated: March 15, 2001. | | | | Pursuant to section 10(d) of the | | | |
| **LaVerne Y. Stringfield,** | | | | **DEPARTMENT OF HEALTH AND HUMAN SERVICES** | | | | | |
| Federal Advisory Committee Act, as | | | |
| *Director, Office of Federal Advisory* | | | |
| amended (5 U.S.C. Appendix 2), notice | | | |
| *Committee Policy.* | | | |
| is hereby given of the following | | | |
| [FR Doc. 01–7213 Filed 3–22–01; 8:45 am] | | | | **National Institutes of Health** | | | | | |
| meeting. | | | |
| **BILLING CODE 4140–01–M** | | | | The meeting will be closed to the | | | |
| **National Cancer Institute; Notice of Closed Meeting** | | | | | |
| public in accordance with the | | | |
| **DEPARTMENT OF HEALTH AND HUMAN SERVICES** | | | |
| provisions set forth in sections | | | |
| 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., | | | |
| Pursuant to section 10(d) of the | | | | | |
| as amended. The grant applications and | | | |
| **National Institutes of Health** | | | | Federal Advisory Committee Act, as | | | | | |
| the discussions could disclose | | | |
| amended (5 U.S.C. Appendix 2), notice | | | | | |
| confidential trade secrets or commercial | | | |
| **National Cancer Institute; Notice of Closed Meeting** | | | | is hereby given of the following | | | | | |
| property such as patentable material, | | | |
| meeting.  The meeting will be closed to the | | | | | |
| and personal information concerning | | | |
| Pursuant to section 10(d) of the | | | | individuals associated with the grant | | | |
| public in accordance with the | | | | | |
| applications, the disclosure of which | | | |
| Federal Advisory Committee Act, as | | | | provisions set forth in sections | | | | | |
| would constitute a clearly unwarranted | | | |
| amended (5 U.S.C. Appendix 2), notice | | | | 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., | | | | | |
| invasion of personal privacy. | | | |
| is hereby given of the following | | | | as amended. The grant applications and | | | | | |
| meeting.  The meeting will be closed to the | | | | the discussions could disclose | | | | | | *Name of Committee:* National Cancer | | | |
| Institute Initial Review Group, Subcommittee | | | |
| confidential trade secrets or commercial | | | | | |
| C—Basic & Preclinical Basic and Preclinical | | | |
| public in accordance with the | | | | property such as patentable material, | | | | | |
| Studies. | | | |
| provisions set forth in sections | | | | and personal information concerning | | | | | |
| *Date:* April 10–11, 2001. | | | |
| 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., | | | | individuals associated with the grant | | | | | |
| *Time:* 7:30 pm to 6 pm. | | | |
| as amended. The grant applications and | | | | applications, the disclosure of which | | | | | |
| *Agenda:* To review and evaluate grant | | | |
| the discussions could disclose | | | | would constitute a clearly unwarranted | | | | | | applications. | | | |
| confidential trade secrets or commercial | | | | invasion of personal privacy. | | | | | | *Place:* Georgetown Holiday Inn, 2101 | | | |
| property such as patentable material, | | | | Wisconsin Avenue, NW., Washington, DC | | | |
| *Name of Committee:* National Cancer | | | | | |
| and personal information concerning | | | | 20007. | | | |
| Institute Special Emphasis Panel, Flexible | | | | | |
| individuals associated with the grant | | | | *Contact Person:* Michael B. Small, PhD, | | | |
| System to Advance Innovative Research for | | | | | |
| Scientific Review Administrator, Grants | | | |
| applications, the disclosure of which | | | | Cancer Drug Discovery by Small Business. | | | | | |
| Review Branch, Division of Extramural | | | |
| would constitute a clearly unwarranted | | | | *Date:* April 19, 2001. | | | | | |
| Activities, National Cancer Institute, National | | | |
| invasion of personal privacy. | | | | *Time:* 8 a.m. to 5 p.m. | | | | | |
| Institutes of Health, 6116 Executive | | | |
| *Agenda:* To review and evaluate grant | | | | | |
| *Name of Committee:* National Cancer | | | | Boulevard, Room 8040, Bethesda, MD 20892, | | | |
| applications. | | | | | |
| Institute Initial Review Group, Subcommittee | | | | 301/402–0996. | | | |
| *Place:* National Cancer Institute, 6130 | | | | | |
| E—Cancer Epidemiology, Prevention & | | | | (Catalogue of Federal Domestic Assistance | | | |
| Executive Boulevard, EPN/Conference J, | | | | | |
| Control. | | | |
| Rockville, MD 20852. | | | | | | Program Nos. 93.392, Cancer Construction; | | | |
| *Date:* April 4–6, 2001. | | | |
| *Contact Person:* Timothy C. Meeker, MD, | | | | | | 93.393, Cancer Cause and Prevention | | | |
| *Time:* 7 a.m. to 1 p.m. | | | |
| Scientific Review Administrator, Special | | | | | | Research; 93.394, Cancer Detection and | | | |
| *Agenda:* To review and evaluate grant | | | |
| Review and Resources Branch, Division of | | | | | | Diagnosis Research; 93.395, Cancer | | | |
| applications. | | | |
| Extramural Activities, National Cancer | | | | | | Treatment Research; 93.396, Cancer Biology | | | |
| *Place:* Holiday Inn—Georgetown, 2101 | | | |
| Institute, 6116 Executive Boulevard, Room | | | | | | Research; 93.397, Cancer Centers Support; | | | |
| Wisconsin Avenue, NW., Washington, DC | | | |
| 8088, Rockville, MD 20852, 301/594–1279, | | | | | | 93.398, Cancer Research Manpower; 93.399, | | | |
| 20007. | | | |
| meekert@mail.nih.gov. | | | | | | Cancer Control, National Institutes of Health, | | | |
| *Contact Person:* Mary C Fletcher, PhD, | | | |
| (Catalogue of Federal Domestic Assistance | | | | | | HHS) | | | |
| Scientific Review Administrator, Grants | | | |
| Program Nos. 93.392, Cancer Construction; | | | | | | Dated: March 15, 2001. | | | |
| Review Branch, Division of Extramural | | | |
| Activities, National Cancer Institute, National | | | | 93.393, Cancer Cause and Prevention | | | | | | **LaVerne Y. Stringfield,** | | | |
| Institutes of Health, 6116 Executive | | | | Research; 93.394, Cancer Detection and | | | | | | *Director, Office of Federal Advisory* | | | |
| Boulevard, Room 8115, Bethesda, MD 20892– | | | | Diagnosis Research; 93.395, Cancer | | | | | |
| *Committee Policy.* | | | |
| 8328. | | | | Treatment Research; 93.396, Cancer Biology | | | | | |
| [FR Doc. 01–7216 Filed 3–22–01; 8:45 am] | | | |
| This notice is being published less than 15 | | | | Research; 93.397, Cancer Centers Support; | | | | | |
| days prior to the meeting due to the timing | | | 93.398, Cancer Research Manpower; 93.399, | | | | | | | **BILLING CODE 4140–01–M** | | | |
| VerDate 11<MAY>2000 | 19:20 Mar 22, 2001 | Jkt 194001 | PO 00000 | | | Frm 00100 | Fmt 4703 | Sfmt 4703 | E:\FR\FM\23MRN1.SGM | | pfrm01 | PsN: 23MRN1 | |